Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Theravance Biopharma, Inc.
The company completed buying or selling a business or major assets. An 8-K is the notice a US public company must file within four business days of a major event.
www.theravance.comAI Executive Summary
AI-powered analysis of 8-K filing content
Zymeworks Inc. completed its acquisition of Theravance Biopharma, Inc. on September 23, 2026, with Theravance becoming a wholly owned subsidiary of Zymeworks. This strategic combination is intended to strengthen both companies' market positions in the biotechnology sector.
Key Takeaways
Acquisition closed on September 23, 2026, as planned under the Agreement and Plan of Merger dated June 28, 2026
Theravance Biopharma now operates as a wholly owned subsidiary of Zymeworks Inc. following the merger
2 more takeaways
Related Filings (2)
2 more filings from Theravance Biopharma, Inc. in the last 90 days
Filing Overview
What This Means
Theravance Biopharma, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.